Whitehawk Therapeutics, Inc.
WHWK Healthcare Biotechnology
Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024. In the quarter to June 2026, revenue grew 33.5%, EPS grew 73.7% and free cash flow grew 72.6%, each against the same quarter a year earlier.
Follow WHWK
Whitehawk Therapeutics, Inc. (WHWK) EV/Sales
As of 16 October 2026, Whitehawk Therapeutics, Inc. (WHWK) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −6.2× (April 2025) to 107× (January 2022); the current reading is higher than 68% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | (87.68%) |
| FY2024 | 1.5× | — |
| FY2023 | −2.2× | — |
| FY2022 | 6.9× | (92.81%) |
| FY2021 | 96.6× | 4,041.77% |
| FY2020 | 2.3× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | −5.7× | — |
| Dec 2024 | 1.5× | — |
| Sep 2024 | −0.2× | — |
| Jun 2024 | −1.6× | — |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −4.0× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| WHWK Whitehawk Therapeutics, Inc. | 1.9× |
| DTIL Precision BioSciences, Inc. compare | 1.9× |
| CHRS Coherus Oncology, Inc. compare | 5.1× |
| ACOG Alpha Cognition Inc. compare | 9.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 29.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)